Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iSpecimen (ISPC) Total Liabilities (2020 - 2025)

iSpecimen has reported Total Liabilities over the past 6 years, most recently at $6.4 million for Q4 2025.

  • Quarterly results put Total Liabilities at $6.4 million for Q4 2025, up 6.69% from a year ago — trailing twelve months through Dec 2025 was $6.4 million (up 6.69% YoY), and the annual figure for FY2025 was $6.4 million, up 6.69%.
  • Total Liabilities for Q4 2025 was $6.4 million at iSpecimen, up from $5.9 million in the prior quarter.
  • Over the last five years, Total Liabilities for ISPC hit a ceiling of $31.2 million in Q1 2021 and a floor of $2.9 million in Q2 2023.
  • Median Total Liabilities over the past 5 years was $5.7 million (2022), compared with a mean of $6.8 million.
  • Biggest five-year swings in Total Liabilities: tumbled 82.0% in 2022 and later soared 103.25% in 2024.
  • iSpecimen's Total Liabilities stood at $5.9 million in 2021, then fell by 27.32% to $4.3 million in 2022, then skyrocketed by 41.07% to $6.1 million in 2023, then decreased by 0.64% to $6.0 million in 2024, then rose by 6.69% to $6.4 million in 2025.
  • The last three reported values for Total Liabilities were $6.4 million (Q4 2025), $5.9 million (Q3 2025), and $5.4 million (Q2 2025) per Business Quant data.